

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

## Duopa (levodopa/carbidopa enteral suspension)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Duopa (levodopa/carbidopa enteral suspension)

### APPROVAL CRITERIA

Requests for Duopa (carbidopa and levodopa enteral suspension) may be approved if the following criteria are met:

- I. Individual has advanced Parkinson's disease (PD) with complicated motor fluctuations; **AND**
- II. Symptoms have not been adequately controlled with optimal medical therapy which includes the following:
  - A. Oral levodopa-carbidopa; **AND**
  - B. Dopamine agonists; **AND**
  - C. One agent from the following classes:
    1. Catechol-0-methyl transferase (COMT) inhibitor; **OR**
    2. Monoamine oxidase B (MAO)-B inhibitor.

Duopa (carbidopa and levodopa enteral suspension) may **not** be approved for the following:

- I. Individual is receiving a nonselective MAO inhibitor (such as phenelzine or tranylcypromine); **OR**
- II. Individuals has a diagnosis of atypical PD or secondary PD.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	NA

\*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

### **Key References:**

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 25, 2018.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.
5. Parkinson's Disease in Adults. NICE Guideline [NG71]. National Institute for Health and Care Excellence. Published Date July 2017. Available at: <https://www.nice.org.uk/guidance/ng71>. Accessed on June 25, 2018.
6. Pahwa R, Factor SA, Lyons KE, et al.; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Neurology. 2006; 66(7):983-995.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.